Keywords: AstraZeneca, Jpb cuts, R&D, Cost-cutting
AstraZeneca to cut another 8,000 jobs as part of $1.8 billion cost-cutting program; unveils new R&D model
Article | 29 January 2010
Anglo-Swedish drug major AstraZeneca, along with revealing 2009 financial results as reported yesterday, when it warned of a likely slowdown in 2010 ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Is the diabetes market facing a blockbuster-free future?
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
